Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this is study is to evaluate the long term safety of DCCR (diazoxide choline
controlled release tablets) in children and adults with Prader-Willi syndrome. After
completion of 1 year in this study, subjects will have the option to continue treatment for
up to 2 additional years.